by
Gus Iversen, Editor in Chief | June 23, 2025
GE HealthCare is collaborating with Stanford Medicine to advance research in total body PET/CT imaging, with a focus on supporting new diagnostic and therapeutic applications in precision medicine.
The initiative centers on developing a next-generation PET/CT platform capable of imaging the entire body simultaneously. Researchers at Stanford’s department of radiology will investigate how this technology might help improve diagnosis, treatment planning, and response monitoring across a range of conditions, including cancer, cardiovascular disease, and neurological disorders.
“PET/CT has revolutionized the way we understand and treat disease by allowing us to visualize biological processes at the cellular level,” said Dr. Quynh-Thu Le, interim chair of the department of radiology at Stanford Medicine. “With total body PET/CT, we can explore new frontiers.”
Ad Statistics
Times Displayed: 2933
Times Visited: 29 Fast-moving cardiac structures have a big impact on imaging. Fujifilm’s SCENARIA View premium performance CT brings solutions to address motion in Coronary CTA while delivering unique dose saving and workflow increasing benefits.
Stanford’s nuclear medicine team also sees opportunities to reduce patient burden. According to Dr. Andrei Iagaru, division chief of nuclear medicine and molecular imaging, total body PET/CT may enable faster scans, lower radiation doses, and support dual-tracer imaging; an approach that could improve pediatric imaging and early disease detection.
The Chicago-based imaging OEM says its total body PET/CT platform is designed to support multi-organ dynamic imaging, ultralow-dose protocols, and greater throughput — features that could help streamline workflows and improve access.
GE HealthCare is working with a global network of clinical partners to explore applications of this high-sensitivity imaging platform beyond oncology. The company positions the technology as a tool for both routine and investigational use, including first-in-human studies for new PET tracers.
Dr. Erin Grady, incoming division chief of nuclear medicine and molecular imaging at Stanford, noted the potential impact on care delivery: “The high throughput we anticipate from this technology could ultimately help improve access for our patients and reduce wait times to their next appointment.”
The effort builds on more than 30 years of collaboration between GE HealthCare and Stanford in molecular imaging research.
